COMMUNIQUÉS West-GlobeNewswire

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
01/07/2026
FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative [...]
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
01/07/2026
Issued 4,444,445 new ordinary shares Priced at €2.70 per share, representing a 14.15% discount on the five-day VWAP and a 12.68% discount to the June 30 closing price The transaction has been structured as a capital [...]
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
01/07/2026
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS , [...]
LiveWorld Names Rob Thomas Vice President, Creative Director to Support Growing Healthcare Creative Practice
01/07/2026
Veteran healthcare creative leader brings deep pharmaceutical expertise and AI-driven innovation to expand agency capabilities CAMPBELL, Calif. and NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC [...]
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
01/07/2026
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE [...]
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
01/07/2026
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris PARIS, France, 1 er juillet 2026 – 14h35 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société »), [...]
Abivax announces trading resumption of its ordinary shares on Euronext Paris
01/07/2026
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a clinical- [...]
Amoéba obtient l’autorisation de mise sur le marché en France pour son biofongicide AXPERA
01/07/2026
Chassieu, 01 juill. 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB) , greentech industrielle spécialisée dans le développement de solutions microbiologiques naturelles basées sur l’exploitation brevetée d’amibes [...]
Amoéba has received marketing authorization in France for its biofungicide AXPERA
01/07/2026
Chassieu, July 01, 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB) , industrial greentech specialized in the development of natural microbiological solutions, announces that it has obtained marketing [...]
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
01/07/2026
SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting [...]
Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29
01/07/2026
CINCINNATI, July 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2026, on Tuesday, July 28, 2026, following the [...]
Creative Medical Technology Holdings Issues Mid-Year Update
01/07/2026
Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: [...]
JenaValve Recaps Key Highlights Including Late-Breaking Clinical Data from New York Valves 2026
01/07/2026
New Evidence Further Defines Distinct Clinical Considerations for Transcatheter Aortic Valve Replacement (TAVR) in Aortic Regurgitation (AR) and Advances Understanding of the Trilogy ® System in Patients with Left [...]
Correction: Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
01/07/2026
Human Appeal supports Syrian farmers through new wheat supply chain project
01/07/2026
The initiative will help more than 1,000 farmers across northwest Syria rebuild livelihoods, strengthen food security and restore agricultural production as they return to their communities MISSION VIEJO, Calif., July [...]
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
01/07/2026
Independent DSMB identifies no safety concerns and recommends continuation of the clinical trial being conducted at the Icahn School of Medicine at Mount Sinai WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees [...]
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
01/07/2026
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
01/07/2026
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidate Poster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal [...]
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
01/07/2026
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]

Pages